Bispecifics for Third Line Therapy of R/R DLBCL : vimarsana.

Experts transition their discussion to highlight the emergence of bispecific antibodies as an additional treatment option for patients with R/R DLBCL.

Related Keywords

, New Treatment Options , Sequencing Therapeutic Choices , Third Line Therapy , Lymphoma , Dlbcl , Diffuse Largeb Cell Lymphoma , Dlbcl Treatments , Dlbcl Therapies , Dlbcl Unmet Needs ,